

B2
Conclude

(a) expression in *E. coli* in culture medium, hirudin or a hirudin derivative which has antithrombotic activity, and which has a defined amino acid, aa_x, at its N terminus, wherein said amino acid aa_x is connected via its N-terminal to a signal peptide to tested;

(b) determining expression rate by measuring said hirudin or hirudin derivative activity in the culture supernatant;

(c) repeating steps (a) and (b) with various signal peptides;

(d) selecting said suitable signal peptide by comparing the expression rates represented by the hirudin antithrombotic activity found in step (b).

B3
C/CP

Claim 8. (Amended) The process of claim 6, further comprising expressing said suitable signal peptide and the desired protein in *E. coli* via a nucleic acid construct, wherein secretion of the desired protein and said suitable peptide occurs with simultaneous elimination of said suitable signal peptide.

REMARKS

Claims 1-14 are pending. Claims 1-5 and 10-14 have been withdrawn from consideration. Claims 6 and 8 have been amended to correct typographical errors. Claim 6, more specifically, was amended to correct the antecedent basis. The claims have not been narrowed by these amendments. Please reconsider this application in light of the following remarks.